Skip to main content

Protagonist Therapeutics — Deal History & Benchmarks

Total Deals
2
Across 1 therapeutic area
Total Deal Value
$1.3B
Cumulative transaction value
Most Active Year
2024
1 deal closed
Primary TA
Gastroenterology
100% of deal activity

Market Analysis

Protagonist Therapeutics has been involved in 2 transactions totaling $1.3B across Gastroenterology. As a licensor (out-licensor), they have demonstrated a preference for licensing partnerships.

Key transactions include J&J ($1B, 2024), Janssen ($340M, 2021).

Their deal activity is concentrated in Gastroenterology (100%) with Peptide assets representing their most common deal type.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How many deals has Protagonist Therapeutics done?
Protagonist Therapeutics has completed 2 verified transactions tracked in our database, spanning from 2021 to 2024. These deals have a combined value of $1.3B.
What is Protagonist Therapeutics's typical deal structure?
Based on 2 deals, Protagonist Therapeutics's transactions show a median upfront payment of $525M. Their most common deal type is licensing, reflecting a preference for licensing partnerships.
What therapeutic areas does Protagonist Therapeutics focus on?
Protagonist Therapeutics focuses on Gastroenterology, representing 100% of their tracked deals.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need a decision for one asset?

The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.

Configure Brief — $2,500About 30 data-backed pages · Invoiced at intake · 30-minute walkthrough